Alimera Sciences

Latest Headlines

Latest Headlines

Alimera, pSivida skyrocket as they give the thrice-rejected Iluvien another go

Partners Alimera and pSivida have three times gone to the FDA with the eye drug Iluvien and three times walked away with little to show for it. But the fourth go-round will be different, the partners believe, and investors would seem to agree, sending the companies' shares skyward on renewed hopes for a 2014 approval.

Alimera, pSivida plummet after FDA rejects eye drug yet again

The FDA has once more rejected Alimera Sciences and pSivida's drug-device combo for diabetic vision loss, roughly halving the companies' stock value and casting further doubt on a treatment plagued by years of failure

Alimera taps Quintiles to commercialize Iluvien

Alimera Sciences is facing an uphill battle getting its chronic diabetic macular edema drug on shelves in Europe, and now the company has recruited Quintiles to manage the European launch of Iluvien.

Sanofi names Gary Nabel chief scientific officer for global R&D

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Venrock gets lean and mean with $350M venture fund

Smaller and more tightly focused will be the dominant style for Venrock Associates' new venture fund. The venture group--a busy player in the biotech space--says that it closed its new healthcare

Alimera shares leap on FDA filing for lead program approval

Alpharetta, GA-based Alimera Sciences managed to buck a rough morning on Wall Street as its shares were buoyed by the announcement that the developer has submitted its lead therapy of diabetic

Alimera slashes IPO price while Codexis delivers at low end

The biotech industry got a mixed read on investors' appetite for IPOs yesterday. The biotech Codexis launched its IPO at the low end of its price range on Wednesday, raising $78 million as it

Alimera files $87M IPO

Georgia-based Alimera Sciences is hoping to raise $87 million in an IPO, according to documents the company filed with the SEC today. The developer will offer 6 million shares at a price range of $15

pSivida shares rocket up on late-stage eye drug data

Shares of pSivida rocketed up in overnight trading after investors got wind of the late-stage success of a new ophthalmic drug the biotech is co-developing with Alimera. The company reported that

Alimera refiles $80M IPO as biotech shares slide

Atlanta-based Alimera Sciences has refiled its IPO, upping the ante to $80 million as it tests investors' appetite for biotech stock. Alimera, which is developing new drugs for retina diseases,